HRP20240808T1 - Formulacije s produljenim oslobađanjem za intraartikularne primjene - Google Patents
Formulacije s produljenim oslobađanjem za intraartikularne primjene Download PDFInfo
- Publication number
- HRP20240808T1 HRP20240808T1 HRP20240808TT HRP20240808T HRP20240808T1 HR P20240808 T1 HRP20240808 T1 HR P20240808T1 HR P20240808T T HRP20240808T T HR P20240808TT HR P20240808 T HRP20240808 T HR P20240808T HR P20240808 T1 HRP20240808 T1 HR P20240808T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- optionally
- preparation according
- water
- oxabicyclo
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 14
- 229920001400 block copolymer Polymers 0.000 claims 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 5
- HNLJEOAFXYIQQM-UHFFFAOYSA-N N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound ClC=1C=C(C=CC=1Cl)NC(=O)C1C2CCC(C1C1=CC=NC=C1)O2 HNLJEOAFXYIQQM-UHFFFAOYSA-N 0.000 claims 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 4
- 239000007900 aqueous suspension Substances 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001993 poloxamer 188 Polymers 0.000 claims 2
- 229940044519 poloxamer 188 Drugs 0.000 claims 2
- 229920001992 poloxamer 407 Polymers 0.000 claims 2
- 229940044476 poloxamer 407 Drugs 0.000 claims 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- HNLJEOAFXYIQQM-YVSFHVDLSA-N (1R,2R,3S,4S)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound ClC=1C=C(C=CC1Cl)NC(=O)[C@H]1[C@H]2CC[C@@H]([C@@H]1C1=CC=NC=C1)O2 HNLJEOAFXYIQQM-YVSFHVDLSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584589P | 2017-11-10 | 2017-11-10 | |
| US201862743864P | 2018-10-10 | 2018-10-10 | |
| EP18807130.2A EP3706710B1 (en) | 2017-11-10 | 2018-11-08 | Extended release formulations for intra-articular applications |
| PCT/IB2018/058788 WO2019092637A1 (en) | 2017-11-10 | 2018-11-08 | Extended release formulations for intra-articular applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240808T1 true HRP20240808T1 (hr) | 2024-09-27 |
Family
ID=64402238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240808TT HRP20240808T1 (hr) | 2017-11-10 | 2018-11-08 | Formulacije s produljenim oslobađanjem za intraartikularne primjene |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210177824A1 (enExample) |
| EP (1) | EP3706710B1 (enExample) |
| JP (1) | JP7284750B2 (enExample) |
| KR (1) | KR20200087138A (enExample) |
| CN (1) | CN111278410A (enExample) |
| AU (1) | AU2018364685B2 (enExample) |
| CA (1) | CA3075722A1 (enExample) |
| CL (1) | CL2020001156A1 (enExample) |
| DK (1) | DK3706710T3 (enExample) |
| ES (1) | ES2981903T3 (enExample) |
| FI (1) | FI3706710T3 (enExample) |
| HR (1) | HRP20240808T1 (enExample) |
| HU (1) | HUE066971T2 (enExample) |
| IL (2) | IL274149B2 (enExample) |
| LT (1) | LT3706710T (enExample) |
| MX (2) | MX2020004477A (enExample) |
| PL (1) | PL3706710T3 (enExample) |
| PT (1) | PT3706710T (enExample) |
| RS (1) | RS65659B1 (enExample) |
| SA (1) | SA520411881B1 (enExample) |
| SI (1) | SI3706710T1 (enExample) |
| TW (2) | TWI813597B (enExample) |
| WO (1) | WO2019092637A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3891154B1 (en) * | 2018-12-06 | 2023-08-16 | Novartis AG | 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage |
| KR20220076371A (ko) * | 2020-11-30 | 2022-06-08 | 주식회사 엘지화학 | 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법 |
| KR20240133027A (ko) | 2023-02-28 | 2024-09-04 | 주식회사 포스테라헬스사이언스 | 올리고펩타이드를 포함하는 서방형 입자 및 이의 제조 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
| CA2947031C (en) * | 2014-05-13 | 2023-01-24 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
-
2018
- 2018-11-08 TW TW107139598A patent/TWI813597B/zh active
- 2018-11-08 TW TW112133215A patent/TW202400164A/zh unknown
- 2018-11-08 HR HRP20240808TT patent/HRP20240808T1/hr unknown
- 2018-11-08 IL IL274149A patent/IL274149B2/en unknown
- 2018-11-08 AU AU2018364685A patent/AU2018364685B2/en active Active
- 2018-11-08 PT PT188071302T patent/PT3706710T/pt unknown
- 2018-11-08 IL IL305541A patent/IL305541A/en unknown
- 2018-11-08 HU HUE18807130A patent/HUE066971T2/hu unknown
- 2018-11-08 CA CA3075722A patent/CA3075722A1/en active Pending
- 2018-11-08 DK DK18807130.2T patent/DK3706710T3/da active
- 2018-11-08 FI FIEP18807130.2T patent/FI3706710T3/fi active
- 2018-11-08 ES ES18807130T patent/ES2981903T3/es active Active
- 2018-11-08 RS RS20240689A patent/RS65659B1/sr unknown
- 2018-11-08 WO PCT/IB2018/058788 patent/WO2019092637A1/en not_active Ceased
- 2018-11-08 LT LTEPPCT/IB2018/058788T patent/LT3706710T/lt unknown
- 2018-11-08 MX MX2020004477A patent/MX2020004477A/es unknown
- 2018-11-08 US US16/761,779 patent/US20210177824A1/en not_active Abandoned
- 2018-11-08 CN CN201880070509.XA patent/CN111278410A/zh active Pending
- 2018-11-08 EP EP18807130.2A patent/EP3706710B1/en active Active
- 2018-11-08 JP JP2020524284A patent/JP7284750B2/ja active Active
- 2018-11-08 KR KR1020207012904A patent/KR20200087138A/ko active Pending
- 2018-11-08 SI SI201831112T patent/SI3706710T1/sl unknown
- 2018-11-08 PL PL18807130.2T patent/PL3706710T3/pl unknown
-
2020
- 2020-04-30 SA SA520411881A patent/SA520411881B1/ar unknown
- 2020-05-04 CL CL2020001156A patent/CL2020001156A1/es unknown
- 2020-07-13 MX MX2023007036A patent/MX2023007036A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| HRP20240808T1 (hr) | Formulacije s produljenim oslobađanjem za intraartikularne primjene | |
| HRP20231018T1 (hr) | Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| JP2006501133A5 (enExample) | ||
| JP2016534142A5 (enExample) | ||
| HRP20211515T1 (hr) | Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni | |
| HRP20130123T1 (hr) | Postupak lijeäśenja bolesti | |
| AR055363A1 (es) | Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion | |
| JP2016513625A5 (enExample) | ||
| JP2009544665A5 (enExample) | ||
| UY38055A (es) | Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario | |
| EP2402003A3 (en) | Diclofenac formulations and methods of use | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu | |
| JP2020500168A5 (enExample) | ||
| HRP20191050T1 (hr) | Pripravak protiv virusnog konjunktivitisa koji sadrži jota-karagenan | |
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| JP2014534215A5 (enExample) | ||
| RU2014115289A (ru) | Композиция пазопаниба | |
| EP4234021A3 (en) | Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy | |
| HRP20191044T1 (hr) | Oftalmološki pripravci i njihova uporaba | |
| JP2021502337A5 (enExample) |